Engineering a Cure: How CAR T-Cell Therapy is Transforming the Fight Against Autoimmune Hemolytic Anemia

The Struggle Against the Self: Sarah’s Story

For Sarah, a 45-year-old teacher from Chicago, life had become a series of hospital visits and exhaustion. Five years ago, she was diagnosed with Autoimmune Hemolytic Anemia (AIHA), a condition where the body’s immune system mistakenly identifies its own red blood cells as foreign invaders and destroys them.

Initially, high-dose steroids and rituximab provided some relief, but the effect was fleeting. Sarah eventually became part of a group of patients known as multirefractory. She had failed four different lines of therapy, including a splenectomy and various immunosuppressants. Her hemoglobin levels remained dangerously low, her skin was perpetually jaundiced from the breakdown of blood cells, and the threat of a life-threatening crisis was always present.